Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2014
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T Y Seiwert, J Fayette, D Cupissol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E Saâda-Bouzid, C Defaucheux, A Karabajakian, et al.
Investigational New Drugs
|
June 5, 2014
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
A Ruzsa, M Sen, M Evans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 26, 2015
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
J Guigay, J Fayette, A F Dillies, et al.
Phytopathology
|
December 11, 2019
Effective Altruism as an Ethical Lens on Research Priorities
K A Garrett, R I Alcalá-Briseño, K F Andersen, et al.
ESMO Open
|
September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study
K Klinghammer, J Fayette, A Kawecki, et al.
ESMO Open
|
April 10, 2026
Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE
J Fayette, C Cropet, C Toullec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2020
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
R L Ferris, R Haddad, C Even, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
P M Clement, T Gauler, J P Machiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
J-P Foy, C Bertolus, M-C Michallet, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2014
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T Y Seiwert, J Fayette, D Cupissol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E Saâda-Bouzid, C Defaucheux, A Karabajakian, et al.
Investigational New Drugs
|
June 5, 2014
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
A Ruzsa, M Sen, M Evans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 26, 2015
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
J Guigay, J Fayette, A F Dillies, et al.
Phytopathology
|
December 11, 2019
Effective Altruism as an Ethical Lens on Research Priorities
K A Garrett, R I Alcalá-Briseño, K F Andersen, et al.
ESMO Open
|
September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study
K Klinghammer, J Fayette, A Kawecki, et al.
ESMO Open
|
April 10, 2026
Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE
J Fayette, C Cropet, C Toullec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2020
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
R L Ferris, R Haddad, C Even, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
P M Clement, T Gauler, J P Machiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
J-P Foy, C Bertolus, M-C Michallet, et al.
Page
of 3